Evidence map›Paper›PMID 34587373›Full record

Trial reportAnnals of clinical and translational neurology2021

Hypertension management in elderly with severe intracerebral hemorrhage.

Jingjing Zhao, Fang Yuan, Feng Fu, Yi Liu, Changhu Xue, Kangjun Wang, Xiangjun Yuan, Dingan Li, Qiuwu Liu, Wei Zhang and 14 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Annals of clinical and translational neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 17 institutions in 2 countries.

Jingjing ZhaoDepartment of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Fang YuanDepartment of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Feng FuDepartment of Neurology, 215 Hospital of Shaanxi NI, Xianyang, 712021, China.
Yi LiuDepartment of Neurology, Ankang Central Hospital, Ankang, 725000, China.
Changhu XueDepartment of Neurology, Xianyang Central Hospital, Xianyang, 712000, China.
Kangjun WangDepartment of Neurology, Hanzhong Central Hospital, Hanzhong, 723000, China.
Xiangjun YuanDepartment of Neurology, Weinan Central Hospital, Weinan, 714000, China.
Dingan LiDepartment of Neurology, Hanzhong Central Hospital, Hanzhong, 723000, China.
Qiuwu LiuDepartment of Neurology, Xi'an 141 Hospital, Xi'an, 710499, China.
Wei ZhangDepartment of Neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, China.
Yi JiaDepartment of Neurology, Xi'an Gaoxin Hospital, Xi'an, 710075, China.
Jianbo HeDepartment of Neurology, Xi'an XD Group Hospital, Xi'an, 710077, China.
Jun ZhouDepartment of Neurology, Shangluo Central Hospital, Shangluo, 726000, China.
Xiaocheng WangDepartment of Neurology, Yulin No.2 Central Hospital, Yulin, 719000, China.
Hua LvDepartment of Neurology, Shaanxi Provincial People's Hospital, Xi'an, 710068, China.
Kang HuoDepartment of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Zhuanhui LiDepartment of Neurology, 521 Hospital of NORINCO Group, Xi'an, 710000, China.
Bei ZhangDepartment of Neurology, The First Affiliated Hospital of Xi'an Medical University, Xi'an, 710021, China.
Chengkai WangDepartment of Neurology, Tongchuan People's Hospital, Tongchuan, China.
Xiaomu WangDepartment of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Hongzeng LiDepartment of Neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, China.
Fang YangDepartment of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Wen JiangDepartment of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.ORCID 0000-0003-0612-2917
CHASE Study Group
Hanzhong Central Hospital · CNJilin City Central Hospital · CNNational Clinical Research Center for Digestive Diseases · CNTang Du Hospital · CNXian Yang Central Hospital · CNXijing Hospital · CNAnkang City Central Hospital · CNChina XD Group (China) · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CNFirst Hospital of Xi'an · CNNorwood Hospital · USShangluo Central Hospital · CNShanxi Medical University · CNThe People's Hospital Tongling · CNWeinan Central Hospital · CNXi'an Chest Hospital · CNXi'an Medical University · CN

Funding

Shaanxi Province Key Research and Development Projects 2017ZDCXL-SF-02-02Shaanxi Province Key Research and Development Projects 2020SF-306
6 · The paper itself

Abstract

objectiveTo explore the effect of individualized blood pressure (BP)-lowering treatment on the outcomes of elderly patients with severe intracerebral hemorrhage (ICH).

methodsWe performed an exploratory analysis of Controlling Hypertension After Severe Cerebrovascular Event (CHASE) trial, which was a multicenter, randomized, controlled clinical trial. Patients with severe ischemic or hemorrhagic stroke (defined as GCS ≤ 12 or NIHSS ≥ 11) were randomized into individualized versus standard BP-lowering treatment in CHASE trial. In this exploratory analysis, patients with severe ICH were included. The primary outcome was the percentage of patients with 90-day functional independence defined as modified Rankin Scale (mRS) ≤2.

resultsWe included 242 patients with severe ICH in the present analysis, consisting of 142 patients aged <65 years and 100 patients aged ≥65 years. There were significant differences between patients aged ≥65 years and <65 years in the proportion of functional independence (47.9% vs. 15.0%, P < 0.001) and good outcome (73.9% vs. 50.0%, P < 0.001) at day 90. In patients aged ≥65 years, the adjusted individualized BP-lowering treatment had an unequivocal effect on the functional independence at day 90 (21.6% vs. 8.2%, odds ratio [OR]: 4.309, 95% confidence interval [CI]: 1.040-17.859, P = 0.044) and improved the neurological deficits at discharge (∆ NIHSS ≥ 4: 64.7% vs. 34.7%, OR: 4.300, 95% CI: 1.599-11.563, P = 0.004).

interpretationCompared with the younger counterparts, the elderly patients (≥65 years) with acute severe ICH might benefit more from individualized BP-lowering treatment.

Indexed as

Outcome Assessment, Health CareAgedAged, 80 and overAntihypertensive AgentsCerebral HemorrhageDisease ManagementFemaleHumansHypertensionMaleMiddle AgedPatient AcuityStrokeAntihypertensive Agents

Identifiers

PMID34587373
PMCPMC8528461
OpenAlexW3201904563

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.